👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

BioNTech predicts return to revenue growth in 2025

Published 01/09/2024, 06:54 AM
Updated 01/09/2024, 08:20 AM
© Reuters. FILE PHOTO: The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/File Photo
PFE
-
BNTX
-

By Ludwig Burger and Linda Pasquini

(Reuters) -BioNTech said on Tuesday it expects to return to revenue growth in 2025 when the ongoing decline in its COVID-19 vaccine business would bottom out, and that it would invest to scale up its oncology business thereafter.

The German biotech firm, which works with Pfizer (NYSE:PFE) on COVID shots, predicted total revenue of about 3 billion euros ($3.28 billion) for 2024, down from revenue of about 4 billion to 5 billion euros it had targeted for 2023.

"BioNTech (NASDAQ:BNTX) expects to grow its topline again in 2025," it said in a statement.

BioNTech's German traded shares were down 0.9% at 1235 GMT as the target for this year fell short of an average analyst revenue estimate, provided by LSEG, of between 3.6 billion and 3.8 billion euros.

According to slides of a presentation to be held at the JP Morgan Healthcare Conference in San Francisco on Tuesday, the company's forecast for 2025 would be helped by higher prices for shots amid a shift from government-sponsored schemes during the pandemic to commercial market models.

Shots combining the company's established mRNA technology against COVID with vaccination against other respiratory diseases such as seasonal flu could also be a revenue booster, the slides showed.

Citing at least 10 late-stage cancer drug studies targeted by the end of 2024, BioNTech said it mapped out plans to launch its first oncology drugs from 2026 onwards, renewing a focus on its traditional roots in oncology.

"We continued our vaccine leadership in the fight against COVID-19 and significantly expanded our mid- and late-stage oncology pipeline," said Ugur Sahin, BioNTech's CEO and co-founder.

Thanks to about 17.5 billion euros in cash, cash equivalents and security investments at the end of 2023 and amid higher interest rates, it said it would generate "significant interest income" in 2024.

The company, which developed the Western world's most widely used COVID-19 shot with Pfizer, said it would retain a strong financial position.

© Reuters. FILE PHOTO: The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/File Photo

BioNTech is scheduled to provide detailed full-year 2024 guidance alongside its 2023 financial results on March 20.

($1 = 0.9141 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.